Dutch study finds out whether gay men prefer daily or on-demand PrEP
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir
Few people with HIV starting raltegravir and dolutegravir change therapy because of side-effects
Proton pump inhibitors may blunt CD4 cell gains, cause immune activation, in people with HIV
Life expectancy now near-normal in people with CD4 counts over 350 a year after starting therapy
Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide
Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds
